Alpha-synuclein aggregation modulators

Neurodegeneration

Current development stage

Discovery

Lead Gen

Lead Opt

Pre-clinical

Partnered/Clinical

Alpha-synuclein (aSyn) is a neuronal protein that misfolds and aggregates in Parkinson’s disease. Accumulation and spread of aSyn in the brain, via a process known as seeding, contributes to dopaminergic neuron dysfunction and degeneration, driving motor and non-motor symptoms. In collaboration with KULeuven we have identified small molecules which prevent Alpha-Synuclein seeding, and these will be further developed as potential therapeutics for Parkinson’s disease.

Target
Alpha-Synuclein
Therapeutic area
Neurodegeneration
Disease
Parkinson's Disease
Development Partner

Collaboration Opportunity

We are currently seeking a strategic partner for the development of this novel class of therapeutics.